APA (7th ed.) Citation

King, B., McMichael, A., Sinclair, R., Vañó-Galvan, S., Wolk, R., Woodworth, D., . . . Roychoudhury, S. (2025). Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. Dermatology & Therapy, 15(12), 3793. https://doi.org/10.1007/s13555-025-01543-7

Chicago Style (17th ed.) Citation

King, Brett, et al. "Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata." Dermatology & Therapy 15, no. 12 (2025): 3793. https://doi.org/10.1007/s13555-025-01543-7.

MLA (9th ed.) Citation

King, Brett, et al. "Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata." Dermatology & Therapy, vol. 15, no. 12, 2025, p. 3793, https://doi.org/10.1007/s13555-025-01543-7.